Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer and Metastasis Reviews
Published in: Cancer and Metastasis Reviews 1-2/2019

01-06-2019 | Pancreatic Cancer | NON-THEMATIC REVIEW

Mucin glycoproteins block apoptosis; promote invasion, proliferation, and migration; and cause chemoresistance through diverse pathways in epithelial cancers

Authors: Ian S. Reynolds, Michael Fichtner, Deborah A. McNamara, Elaine W. Kay, Jochen H.M. Prehn, John P. Burke

Published in: Cancer and Metastasis Reviews | Issue 1-2/2019

Login to get access

Abstract

Overexpression of mucin glycoproteins has been demonstrated in many epithelial-derived cancers. The significance of this overexpression remains uncertain. The aim of this paper was to define the association of mucin glycoproteins with apoptosis, cell growth, invasion, migration, adhesion, and clonogenicity in vitro as well as tumor growth, tumorigenicity, and metastasis in vivo in epithelial-derived cancers by performing a systematic review of all published data. A systematic review of PubMed, Embase, and the Cochrane Central Register of Controlled Trials was performed to identify all papers that evaluated the association between mucin glycoproteins with apoptosis, cell growth, invasion, migration, adhesion, and clonogenicity in vitro as well as tumor growth, tumorigenicity, and metastasis in vivo in epithelial-derived cancers. PRISMA guidelines were adhered to. Results of individual studies were extracted and pooled together based on the organ in which the cancer was derived from. The initial search revealed 2031 papers, of which 90 were deemed eligible for inclusion in the study. The studies included details on MUC1, MUC2, MUC4, MUC5AC, MUC5B, MUC13, and MUC16. The majority of studies evaluated MUC1. MUC1 overexpression was consistently associated with resistance to apoptosis and resistance to chemotherapy. There was also evidence that overexpression of MUC2, MUC4, MUC5AC, MUC5B, MUC13, and MUC16 conferred resistance to apoptosis in epithelial-derived cancers. The overexpression of mucin glycoproteins is associated with resistance to apoptosis in numerous epithelial cancers. They cause resistance through diverse signaling pathways. Targeting the expression of mucin glycoproteins represents a potential therapeutic target in the treatment of epithelial-derived cancers.
Literature
1.
Krysko, O., Aaes, T. L., Kagan, V. E., D’Herde, K., Bachert, C., Leybaert, L., et al. (2017). Necroptotic cell death in anti-cancer therapy. Immunological Reviews, 280(1), 207–219.CrossRefPubMed
2.
Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell, 144(5), 646–674.CrossRefPubMed
3.
Laubenbacher, R., Hower, V., Jarrah, A., Torti, S. V., Shulaev, V., Mendes, P., et al. (2009). A systems biology view of cancer. Biochimica et Biophysica Acta, 1796(2), 129–139.PubMedPubMedCentral
4.
Eum, K. H., & Lee, M. (2011). Crosstalk between autophagy and apoptosis in the regulation of paclitaxel-induced cell death in v-Ha-ras-transformed fibroblasts. Molecular and Cellular Biochemistry, 348(1–2), 61–68.CrossRefPubMed
5.
Kerr, J. F., Wyllie, A. H., & Currie, A. R. (1972). Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. British Journal of Cancer, 26(4), 239–257.CrossRefPubMedPubMedCentral
6.
Ghobrial, I. M., Witzig, T. E., & Adjei, A. A. (2005). Targeting apoptosis pathways in cancer therapy. CA: a Cancer Journal for Clinicians, 55(3), 178–194.
7.
Joshi, S., Kumar, S., Choudhury, A., Ponnusamy, M. P., & Batra, S. K. (2014). Altered mucins (MUC) trafficking in benign and malignant conditions. Oncotarget, 5(17), 7272–7284.CrossRefPubMedPubMedCentral
8.
Jonckheere, N., Skrypek, N., Frenois, F., & Van Seuningen, I. (2013). Membrane-bound mucin modular domains: from structure to function. Biochimie, 95(6), 1077–1086.CrossRefPubMed
9.
Albrecht, H., & Carraway, K. L., 3rd. (2011). MUC1 and MUC4: switching the emphasis from large to small. Cancer Biotherapy & Radiopharmaceuticals., 26(3), 261–271.CrossRef
10.
11.
Senapati, S., Das, S., & Batra, S. K. (2010). Mucin-interacting proteins: from function to therapeutics. Trends in Biochemical Sciences., 35(4), 236–245.CrossRefPubMed
12.
Rachagani, S., Torres, M. P., Moniaux, N., & Batra, S. K. (2009). Current status of mucins in the diagnosis and therapy of cancer. BioFactors (Oxford, England)., 35(6), 509–527.CrossRefPubMedCentral
13.
Kaur, S., Kumar, S., Momi, N., Sasson, A. R., & Batra, S. K. (2013). Mucins in pancreatic cancer and its microenvironment. Nature Reviews Gastroenterology & Hepatology., 10(10), 607–620.CrossRef
14.
Chaturvedi, P., Singh, A. P., & Batra, S. K. (2008). Structure, evolution, and biology of the MUC4 mucin. FASEB Journal: official publication of the Federation of American Societies for Experimental Biology., 22(4), 966–981.CrossRef
15.
Tarang, S., Kumar, S., & Batra, S. K. (2012). Mucins and toll-like receptors: kith and kin in infection and cancer. Cancer Letters., 321(2), 110–119.CrossRefPubMedPubMedCentral
16.
van der Sluis, M., Melis, M. H., Jonckheere, N., Ducourouble, M. P., Buller, H. A., Renes, I., et al. (2004). The murine Muc2 mucin gene is transcriptionally regulated by the zinc-finger GATA-4 transcription factor in intestinal cells. Biochemical and Biophysical Research Communications., 325(3), 952–960.CrossRefPubMed
17.
Niv, Y. (2016). Mucin gene expression in the intestine of ulcerative colitis patients: a systematic review and meta-analysis. European Journal of Gastroenterology & Hepatology, 28(11), 1241–1245.CrossRef
18.
Jonckheere, N., Skrypek, N., & Van Seuningen, I. (2014). Mucins and tumor resistance to chemotherapeutic drugs. Biochimica et Biophysica Acta, 1846(1), 142–151.PubMed
19.
Moniaux, N., Andrianifahanana, M., Brand, R. E., & Batra, S. K. (2004). Multiple roles of mucins in pancreatic cancer, a lethal and challenging malignancy. British Journal of Cancer., 91(9), 1633–1638.CrossRefPubMedPubMedCentral
20.
Jonckheere, N., & Van Seuningen, I. (2010). The membrane-bound mucins: from cell signalling to transcriptional regulation and expression in epithelial cancers. Biochimie, 92(1), 1–11.CrossRefPubMed
21.
Mukhopadhyay, P., Chakraborty, S., Ponnusamy, M. P., Lakshmanan, I., Jain, M., & Batra, S. K. (2011). Mucins in the pathogenesis of breast cancer: implications in diagnosis, prognosis and therapy. Biochimica et Biophysica Acta, 1815(2), 224–240.PubMedPubMedCentral
22.
Lakshmanan, I., Ponnusamy, M. P., Macha, M. A., Haridas, D., Majhi, P. D., Kaur, S., et al. (2015). Mucins in lung cancer: diagnostic, prognostic, and therapeutic implications. Journal of Thoracic Oncology: official publication of the International Association for the Study of Lung Cancer., 10(1), 19–27.CrossRef
23.
Krishn, S. R., Kaur, S., Smith, L. M., Johansson, S. L., Jain, M., Patel, A., et al. (2016). Mucins and associated glycan signatures in colon adenoma-carcinoma sequence: prospective pathological implication(s) for early diagnosis of colon cancer. Cancer letters., 374(2), 304–314.CrossRefPubMedPubMedCentral
24.
Pai, P., Rachagani, S., Dhawan, P., & Batra, S. K. (2016). Mucins and Wnt/beta-catenin signaling in gastrointestinal cancers: an unholy nexus. Carcinogenesis, 37(3), 223–232.CrossRefPubMedPubMedCentral
25.
Kumar, S., Das, S., Rachagani, S., Kaur, S., Joshi, S., Johansson, S. L., et al. (2015). NCOA3-mediated upregulation of mucin expression via transcriptional and post-translational changes during the development of pancreatic cancer. Oncogene, 34(37), 4879–4889.CrossRefPubMed
26.
Perrais, M., Rousseaux, C., Ducourouble, M. P., Courcol, R., Vincent, P., Jonckheere, N., et al. (2014). Helicobacter pylori urease and flagellin alter mucin gene expression in human gastric cancer cells. Gastric Cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association., 17(2), 235–246.CrossRef
27.
Shibahara, H., Higashi, M., Yokoyama, S., Rousseau, K., Kitazono, I., Osako, M., et al. (2014). A comprehensive expression analysis of mucins in appendiceal carcinoma in a multicenter study: MUC3 is a novel prognostic factor. PLoS One, 9(12), e115613.CrossRefPubMedPubMedCentral
28.
Jonckheere, N., & Van Seuningen, I. (2008). The membrane-bound mucins: how large O-glycoproteins play key roles in epithelial cancers and hold promise as biological tools for gene-based and immunotherapies. Critical Reviews in Oncogenesis., 14(2–3), 177–196.CrossRefPubMed
29.
Andrianifahanana, M., Moniaux, N., Schmied, B. M., Ringel, J., Friess, H., Hollingsworth, M. A., et al. (2001). Mucin (MUC) gene expression in human pancreatic adenocarcinoma and chronic pancreatitis: a potential role of MUC4 as a tumor marker of diagnostic significance. Clinical Cancer Research : an official journal of the American Association for Cancer Research, 7(12), 4033–4040.
30.
Mukhopadhyay, P., Lakshmanan, I., Ponnusamy, M. P., Chakraborty, S., Jain, M., Pai, P., et al. (2013). MUC4 overexpression augments cell migration and metastasis through EGFR family proteins in triple negative breast cancer cells. PLoS One, 8(2), e54455.CrossRefPubMedPubMedCentral
31.
Senapati, S., Chaturvedi, P., Sharma, P., Venkatraman, G., Meza, J. L., El-Rifai, W., et al. (2008). Deregulation of MUC4 in gastric adenocarcinoma: potential pathobiological implication in poorly differentiated non-signet ring cell type gastric cancer. British Journal of Cancer, 99(6), 949–956.CrossRefPubMedPubMedCentral
32.
Singh, A. P., Chauhan, S. C., Bafna, S., Johansson, S. L., Smith, L. M., Moniaux, N., et al. (2006). Aberrant expression of transmembrane mucins, MUC1 and MUC4, in human prostate carcinomas. The Prostate, 66(4), 421–429.CrossRefPubMed
33.
Kaur, S., Momi, N., Chakraborty, S., Wagner, D. G., Horn, A. J., Lele, S. M., et al. (2014). Altered expression of transmembrane mucins, MUC1 and MUC4, in bladder cancer: pathological implications in diagnosis. PLoS One, 9(3), e92742.CrossRefPubMedPubMedCentral
34.
Moher, D., Shamseer, L., Clarke, M., Ghersi, D., Liberati, A., Petticrew, M., et al. (2015). Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Systematic Reviews, 4, 1.CrossRefPubMedPubMedCentral
35.
Dilly, A. K., Honick, B. D., Lee, Y. J., Guo, Z. S., Zeh, H. J., Bartlett, D. L., et al. (2017). Targeting G-protein coupled receptor-related signaling pathway in a murine xenograft model of appendiceal pseudomyxoma peritonei. Oncotarget, 8(63), 106888–106900.CrossRefPubMedPubMedCentral
36.
Garcia, E. P., Tiscornia, I., Libisch, G., Trajtenberg, F., Bollati-Fogolin, M., Rodriguez, E., et al. (2016). MUC5B silencing reduces chemo-resistance of MCF-7 breast tumor cells and impairs maturation of dendritic cells. International Journal of Oncology, 48(5), 2113–2123.CrossRefPubMed
37.
Lakshmanan, I., Ponnusamy, M. P., Das, S., Chakraborty, S., Haridas, D., Mukhopadhyay, P., et al. (2012). MUC16 induced rapid G2/M transition via interactions with JAK2 for increased proliferation and anti-apoptosis in breast cancer cells. Oncogene, 31(7), 805–817.CrossRefPubMed
38.
Workman, H. C., Sweeney, C., & Carraway, K. L., 3rd. (2009). The membrane mucin Muc4 inhibits apoptosis induced by multiple insults via ErbB2-dependent and ErbB2-independent mechanisms. Cancer Research, 69(7), 2845–2852.CrossRefPubMedPubMedCentral
39.
Hattrup, C. L., & Gendler, S. J. (2006). MUC1 alters oncogenic events and transcription in human breast cancer cells. Breast Cancer Research, 8(4), R37.CrossRefPubMedPubMedCentral
40.
Schroeder, J. A., Masri, A. A., Adriance, M. C., Tessier, J. C., Kotlarczyk, K. L., Thompson, M. C., et al. (2004). MUC1 overexpression results in mammary gland tumorigenesis and prolonged alveolar differentiation. Oncogene, 23(34), 5739–5747.CrossRefPubMed
41.
Li, Y., Pang, Z., Dong, X., Liao, X., Deng, H., Liao, C., et al. (2018). MUC1 induces M2 type macrophage influx during postpartum mammary gland involution and triggers breast cancer. Oncotarget, 9(3), 3446–3458.PubMed
42.
Jin, W., Liao, X., Lv, Y., Pang, Z., Wang, Y., Li, Q., et al. (2017). MUC1 induces acquired chemoresistance by upregulating ABCB1 in EGFR-dependent manner. Cell Death & Disease, 8(8), e2980.CrossRef
43.
Zhu, X., Long, X., Luo, X., Song, Z., Li, S., & Wang, H. (2016). Abrogation of MUC5AC expression contributes to the apoptosis and cell cycle arrest of colon cancer cells. Cancer Biotherapy & Radiopharmaceuticals, 31(7), 261–267.CrossRef
44.
Sheng, Y. H., He, Y., Hasnain, S. Z., Wang, R., Tong, H., Clarke, D. T., et al. (2017). MUC13 protects colorectal cancer cells from death by activating the NF-kappaB pathway and is a potential therapeutic target. Oncogene, 36(5), 700–713.CrossRefPubMed
45.
Chen, Q., Li, D., Ren, J., Li, C., & Xiao, Z. X. (2013). MUC1 activates JNK1 and inhibits apoptosis under genotoxic stress. Biochemical and Biophysical Research Communications, 440(1), 179–183.CrossRefPubMed
46.
Ren, J., Agata, N., Chen, D., Li, Y., Yu, W. H., Huang, L., et al. (2004). Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents. Cancer Cell, 5(2), 163–175.CrossRefPubMedPubMedCentral
47.
Costa, N. R., Paulo, P., Caffrey, T., Hollingsworth, M. A., & Santos-Silva, F. (2011). Impact of MUC1 mucin downregulation in the phenotypic characteristics of MKN45 gastric carcinoma cell line. PLoS One, 6(11), e26970.CrossRefPubMedPubMedCentral
48.
Yi, F. T., & Lu, Q. P. (2017). Mucin 1 promotes radioresistance in hepatocellular carcinoma cells through activation of JAK2/STAT3 signaling. Oncology Letters, 14(6), 7571–7576.PubMedPubMedCentral
49.
Yuan, H., Wang, J., Wang, F., Zhang, N., Li, Q., Xie, F., et al. (2015). Mucin 1 gene silencing inhibits the growth of SMMC-7721 human hepatoma cells through Bax-mediated mitochondrial and caspase-8-mediated death receptor apoptotic pathways. Molecular Medicine Reports, 12(5), 6782–6788.CrossRefPubMedPubMedCentral
50.
Li, Q., Wang, F., Liu, G., Yuan, H., Chen, T., Wang, J., et al. (2014). Impact of Mucin1 knockdown on the phenotypic characteristics of the human hepatocellular carcinoma cell line SMMC-7721. Oncology Reports, 31(6), 2811–2819.CrossRefPubMed
51.
Xu, T., Li, D., Wang, H., Zheng, T., Wang, G., & Xin, Y. (2017). MUC1 downregulation inhibits non-small cell lung cancer progression in human cell lines. Experimental and Therapeutic Medicine, 14(5), 4443–4447.PubMedPubMedCentral
52.
Xu, X., Wells, A., Padilla, M. T., Kato, K., Kim, K. C., & Lin, Y. (2014). A signaling pathway consisting of miR-551b, catalase and MUC1 contributes to acquired apoptosis resistance and chemoresistance. Carcinogenesis, 35(11), 2457–2466.CrossRefPubMedPubMedCentral
53.
Gao, J., McConnell, M. J., Yu, B., Li, J., Balko, J. M., Black, E. P., et al. (2009). MUC1 is a downstream target of STAT3 and regulates lung cancer cell survival and invasion. International Journal of Oncology, 35(2), 337–345.PubMedPubMedCentral
54.
Grover, P., Nath, S., Nye, M. D., Zhou, R., Ahmad, M., & Mukherjee, P. (2018). SMAD4-independent activation of TGF-beta signaling by MUC1 in a human pancreatic cancer cell line. Oncotarget, 9(6), 6897–6910.CrossRefPubMedPubMedCentral
55.
Zhao, P., Meng, M., Xu, B., Dong, A., Ni, G., & Lu, L. (2017). Decreased expression of MUC1 induces apoptosis and inhibits migration in pancreatic cancer PANC-1 cells via regulation of Slug pathway. Cancer Biomarkers, 20(4), 469–476.CrossRefPubMed
56.
Trehoux, S., Duchene, B., Jonckheere, N., & Van Seuningen, I. (2015). The MUC1 oncomucin regulates pancreatic cancer cell biological properties and chemoresistance. Implication of p42-44 MAPK, Akt, Bcl-2 and MMP13 pathways. Biochemical and Biophysical Research Communications, 456(3), 757–762.CrossRefPubMed
57.
Jonckheere, N., Skrypek, N., Merlin, J., Dessein, A. F., Dumont, P., Leteurtre, E., et al. (2012). The mucin MUC4 and its membrane partner ErbB2 regulate biological properties of human CAPAN-2 pancreatic cancer cells via different signalling pathways. PLoS One, 7(2), e32232.CrossRefPubMedPubMedCentral
58.
Bafna, S., Kaur, S., Momi, N., & Batra, S. K. (2009). Pancreatic cancer cells resistance to gemcitabine: the role of MUC4 mucin. British Journal of Cancer, 101(7), 1155–1161.CrossRefPubMedPubMedCentral
59.
Chaturvedi, P., Singh, A. P., Moniaux, N., Senapati, S., Chakraborty, S., Meza, J. L., et al. (2007). MUC4 mucin potentiates pancreatic tumor cell proliferation, survival, and invasive properties and interferes with its interaction to extracellular matrix proteins. Molecular Cancer Research: MCR, 5(4), 309–320.CrossRefPubMed
60.
Hoshi, H., Sawada, T., Uchida, M., Iijima, H., Kimura, K., Hirakawa, K., et al. (2013). MUC5AC protects pancreatic cancer cells from TRAIL-induced death pathways. International Journal of Oncology, 42(3), 887–893.CrossRefPubMed
61.
Sheng, Y., Ng, C. P., Lourie, R., Shah, E. T., He, Y., Wong, K. Y., et al. (2017). MUC13 overexpression in renal cell carcinoma plays a central role in tumor progression and drug resistance. International Journal of Cancer, 140(10), 2351–2363.CrossRefPubMed
62.
Zhao, Q., Piyush, T., Chen, C., Hollingsworth, M. A., Hilkens, J., Rhodes, J. M., et al. (2014). MUC1 extracellular domain confers resistance of epithelial cancer cells to anoikis. Cell Death & Disease, e1438, 5.
63.
Yin, L., Li, Y., Ren, J., Kuwahara, H., & Kufe, D. (2003). Human MUC1 carcinoma antigen regulates intracellular oxidant levels and the apoptotic response to oxidative stress. The Journal of Biological Chemistry, 278(37), 35458–35464.CrossRefPubMed
64.
Raina, D., Ahmad, R., Kumar, S., Ren, J., Yoshida, K., Kharbanda, S., et al. (2006). MUC1 oncoprotein blocks nuclear targeting of c-Abl in the apoptotic response to DNA damage. The EMBO Journal, 25(16), 3774–3783.CrossRefPubMedPubMedCentral
65.
Rowson-Hodel, A. R., Wald, J. H., Hatakeyama, J., O’Neal, W. K., Stonebraker, J. R., VanderVorst, K., et al. (2018). Membrane mucin Muc4 promotes blood cell association with tumor cells and mediates efficient metastasis in a mouse model of breast cancer. Oncogene, 37(2), 197–207.CrossRefPubMed
66.
Astashchanka, A., Shroka, T. M., & Jacobsen, B. M. (2018). Mucin 2 (MUC2) modulates the aggressiveness of breast cancer. Breast Cancer Research and Treatment.
67.
Reinartz, S., Failer, S., Schuell, T., & Wagner, U. (2012). CA125 (MUC16) gene silencing suppresses growth properties of ovarian and breast cancer cells. European Journal of Cancer (Oxford, England: 1990), 48(10), 1558–1569.CrossRef
68.
Liu, Q., Cheng, Z., Luo, L., Yang, Y., Zhang, Z., Ma, H., et al. (2016). C-terminus of MUC16 activates Wnt signaling pathway through its interaction with beta-catenin to promote tumorigenesis and metastasis. Oncotarget, 7(24), 36800–36813.PubMedPubMedCentral
69.
Valque, H., Gouyer, V., Gottrand, F., & Desseyn, J. L. (2012). MUC5B leads to aggressive behavior of breast cancer MCF7 cells. PLoS One, 7(10), e46699.CrossRefPubMedPubMedCentral
70.
Fessler, S. P., Wotkowicz, M. T., Mahanta, S. K., & Bamdad, C. (2009). MUC1* is a determinant of trastuzumab (Herceptin) resistance in breast cancer cells. Breast Cancer Research and Treatment, 118(1), 113–124.CrossRefPubMed
71.
Chen, A. C., Migliaccio, I., Rimawi, M., Lopez-Tarruella, S., Creighton, C. J., Massarweh, S., et al. (2012). Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapies. Breast Cancer Research and Treatment, 134(2), 583–593.CrossRefPubMedPubMedCentral
72.
Maeda, T., Hiraki, M., Jin, C., Rajabi, H., Tagde, A., Alam, M., et al. (2018). MUC1-C induces PD-L1 and immune evasion in triple-negative breast cancer. Cancer Research., 78(1), 205–215.CrossRefPubMed
73.
Alam, M., Rajabi, H., Ahmad, R., Jin, C., & Kufe, D. (2014). Targeting the MUC1-C oncoprotein inhibits self-renewal capacity of breast cancer cells. Oncotarget, 5(9), 2622–2634.CrossRefPubMedPubMedCentral
74.
Kharbanda, A., Rajabi, H., Jin, C., Raina, D., & Kufe, D. (2013). Oncogenic MUC1-C promotes tamoxifen resistance in human breast cancer. Molecular Cancer Research: MCR, 11(7), 714–723.CrossRefPubMed
75.
Raina, D., Uchida, Y., Kharbanda, A., Rajabi, H., Panchamoorthy, G., Jin, C., et al. (2014). Targeting the MUC1-C oncoprotein downregulates HER2 activation and abrogates trastuzumab resistance in breast cancer cells. Oncogene, 33(26), 3422–3431.CrossRefPubMed
76.
Uchida, Y., Raina, D., Kharbanda, S., & Kufe, D. (2013). Inhibition of the MUC1-C oncoprotein is synergistic with cytotoxic agents in the treatment of breast cancer cells. Cancer Biology & Therapy, 14(2), 127–134.CrossRef
77.
Das, S., Rachagani, S., Sheinin, Y., Smith, L. M., Gurumurthy, C. B., Roy, H. K., et al. (2016). Mice deficient in Muc4 are resistant to experimental colitis and colitis-associated colorectal cancer. Oncogene, 35(20), 2645–2654.CrossRefPubMed
78.
Gupta, B. K., Maher, D. M., Ebeling, M. C., Stephenson, P. D., Puumala, S. E., Koch, M. R., et al. (2014). Functions and regulation of MUC13 mucin in colon cancer cells. Journal of Gastroenterology, 49(10), 1378–1391.CrossRefPubMed
79.
Bruyere, E., Jonckheere, N., Frenois, F., Mariette, C., & Van Seuningen, I. (2011). The MUC4 membrane-bound mucin regulates esophageal cancer cell proliferation and migration properties: Implication for S100A4 protein. Biochemical and Biophysical Research Communications, 413(2), 325–329.CrossRefPubMed
80.
Gronnier, C., Bruyere, E., Lahdaoui, F., Jonckheere, N., Perrais, M., Leteurtre, E., et al. (2014). The MUC1 mucin regulates the tumorigenic properties of human esophageal adenocarcinomatous cells. Biochimica et Biophysica Acta, 1843(11), 2432–2437.CrossRefPubMed
81.
Lahdaoui, F., Messager, M., Vincent, A., Hec, F., Gandon, A., Warlaumont, M., et al. (2017). Depletion of MUC5B mucin in gastrointestinal cancer cells alters their tumorigenic properties: implication of the Wnt/beta-catenin pathway. The Biochemical Journal, 474(22), 3733–3746.CrossRefPubMed
82.
Deng, M., Jing, D. D., & Meng, X. J. (2013). Effect of MUC1 siRNA on drug resistance of gastric cancer cells to trastuzumab. Asian Pacific Journal of Cancer Prevention: APJCP, 14(1), 127–131.CrossRefPubMed
83.
Shi, M., Yang, Z., Hu, M., Liu, D., Hu, Y., Qian, L., et al. (2013). Catecholamine-induced beta2-adrenergic receptor activation mediates desensitization of gastric cancer cells to trastuzumab by upregulating MUC4 expression. Journal of Immunology (Baltimore, Md: 1950), 190(11), 5600–5608.CrossRef
84.
Macha, M. A., Rachagani, S., Pai, P., Gupta, S., Lydiatt, W. M., Smith, R. B., et al. (2015). MUC4 regulates cellular senescence in head and neck squamous cell carcinoma through p16/Rb pathway. Oncogene, 34(13), 1698–1708.CrossRefPubMed
85.
Lakshmanan, I., Salfity, S., Seshacharyulu, P., Rachagani, S., Thomas, A., Das, S., et al. (2017). MUC16 regulates TSPYL5 for lung cancer cell growth and chemoresistance by suppressing p53. Clinical Cancer Research, 23(14), 3906–3917.CrossRefPubMedPubMedCentral
86.
Lakshmanan, I., Rachagani, S., Hauke, R., Krishn, S. R., Paknikar, S., Seshacharyulu, P., et al. (2016). MUC5AC interactions with integrin beta4 enhances the migration of lung cancer cells through FAK signaling. Oncogene, 35(31), 4112–4121.CrossRefPubMedPubMedCentral
87.
Majhi, P. D., Lakshmanan, I., Ponnusamy, M. P., Jain, M., Das, S., Kaur, S., et al. (2013). Pathobiological implications of MUC4 in non-small-cell lung cancer. Journal of Thoracic Oncology: official publication of the International Association for the Study of Lung Cancer, 8(4), 398–407.CrossRef
88.
Kanwal, M., Ding, X. J., Song, X., Zhou, G. B., & Cao, Y. (2018). MUC16 overexpression induced by gene mutations promotes lung cancer cell growth and invasion. Oncotarget, 9(15), 12226–12239.CrossRefPubMedPubMedCentral
89.
Raina, D., Kosugi, M., Ahmad, R., Panchamoorthy, G., Rajabi, H., Alam, M., et al. (2011). Dependence on the MUC1-C oncoprotein in non-small cell lung cancer cells. Molecular Cancer Therapeutics, 10(5), 806–816.CrossRefPubMedPubMedCentral
90.
Bouillez, A., Gnemmi, V., Gaudelot, K., Hemon, B., Ringot, B., Pottier, N., et al. (2014). MUC1-C nuclear localization drives invasiveness of renal cancer cells through a sheddase/gamma secretase dependent pathway. Oncotarget, 5(3), 754–763.CrossRefPubMedPubMedCentral
91.
Aubert, S., Fauquette, V., Hemon, B., Lepoivre, R., Briez, N., Bernard, D., et al. (2009). MUC1, a new hypoxia inducible factor target gene, is an actor in clear renal cell carcinoma tumor progression. Cancer Research, 69(14), 5707–5715.CrossRefPubMed
92.
Alam, M., Ahmad, R., Rajabi, H., Kharbanda, A., & Kufe, D. (2013). MUC1-C oncoprotein activates ERK-->C/EBPbeta signaling and induction of aldehyde dehydrogenase 1A1 in breast cancer cells. The Journal of Biological Chemistry, 288(43), 30892–30903.CrossRefPubMedPubMedCentral
93.
Mimeault, M., Johansson, S. L., Senapati, S., Momi, N., Chakraborty, S., & Batra, S. K. (2010). MUC4 down-regulation reverses chemoresistance of pancreatic cancer stem/progenitor cells and their progenies. Cancer Letters, 295(1), 69–84.CrossRefPubMedPubMedCentral
94.
Huang, W. C., Chan, M. L., Chen, M. J., Tsai, T. H., & Chen, Y. J. (2016). Modulation of macrophage polarization and lung cancer cell stemness by MUC1 and development of a related small-molecule inhibitor pterostilbene. Oncotarget, 7(26), 39363–39375.PubMedPubMedCentral
95.
Wang, R., Yang, L., Li, S., Ye, D., Yang, L., Liu, Q., et al. (2018). Quercetin inhibits breast cancer stem cells via downregulation of aldehyde dehydrogenase 1A1 (ALDH1A1), chemokine receptor type 4 (CXCR4), mucin 1 (MUC1), and epithelial cell adhesion molecule (EpCAM). Medical Science Monitor: international medical journal of experimental and clinical research, 24, 412–420.CrossRef
96.
Hiraki, M., Maeda, T., Bouillez, A., Alam, M., Tagde, A., Hinohara, K., et al. (2017). MUC1-C activates BMI1 in human cancer cells. Oncogene, 36(20), 2791–2801.CrossRefPubMed
97.
Zhou, N., Zhang, Y., Zhang, X., Lei, Z., Hu, R., Li, H., et al. (2015). Exposure of tumor-associated macrophages to apoptotic MCF-7 cells promotes breast cancer growth and metastasis. International Journal of Molecular Sciences, 16(6), 11966–11982.CrossRefPubMedPubMedCentral
98.
Engelmann, K., Shen, H., & Finn, O. J. (2008). MCF7 side population cells with characteristics of cancer stem/progenitor cells express the tumor antigen MUC1. Cancer research, 68(7), 2419–2426.CrossRefPubMed
99.
Das, S., Rachagani, S., Torres-Gonzalez, M. P., Lakshmanan, I., Majhi, P. D., Smith, L. M., et al. (2015). Carboxyl-terminal domain of MUC16 imparts tumorigenic and metastatic functions through nuclear translocation of JAK2 to pancreatic cancer cells. Oncotarget, 6(8), 5772–5787.CrossRefPubMedPubMedCentral
100.
Skrypek, N., Duchene, B., Hebbar, M., Leteurtre, E., van Seuningen, I., & Jonckheere, N. (2013). The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the Concentrative Nucleoside Transporter family. Oncogene, 32(13), 1714–1723.CrossRefPubMed
101.
Lahdaoui, F., Delpu, Y., Vincent, A., Renaud, F., Messager, M., Duchene, B., et al. (2015). miR-219-1-3p is a negative regulator of the mucin MUC4 expression and is a tumor suppressor in pancreatic cancer. Oncogene, 34(6), 780–788.CrossRefPubMed
102.
Trehoux, S., Lahdaoui, F., Delpu, Y., Renaud, F., Leteurtre, E., Torrisani, J., et al. (2015). Micro-RNAs miR-29a and miR-330-5p function as tumor suppressors by targeting the MUC1 mucin in pancreatic cancer cells. Biochimica et Biophysica Acta, 1853(10 Pt A), 2392–2403.CrossRefPubMed
103.
Jahan, R., Macha, M. A., Rachagani, S., Das, S., Smith, L. M., Kaur, S., et al. (2018). Axed MUC4 (MUC4/X) aggravates pancreatic malignant phenotype by activating integrin-beta1/FAK/ERK pathway. Biochimica et Biophysica Acta - Molecular Basis of Disease, 1864(8), 2538–2549.CrossRefPubMed
104.
Muniyan, S., Haridas, D., Chugh, S., Rachagani, S., Lakshmanan, I., Gupta, S., et al. (2016). MUC16 contributes to the metastasis of pancreatic ductal adenocarcinoma through focal adhesion mediated signaling mechanism. Genes & Cancer, 7(3–4), 110–124.
105.
Seshacharyulu, P., Ponnusamy, M. P., Rachagani, S., Lakshmanan, I., Haridas, D., Yan, Y., et al. (2015). Targeting EGF-receptor(s) - STAT1 axis attenuates tumor growth and metastasis through downregulation of MUC4 mucin in human pancreatic cancer. Oncotarget, 6(7), 5164–5181.CrossRefPubMed
106.
Lakshmanan, I., Seshacharyulu, P., Haridas, D., Rachagani, S., Gupta, S., Joshi, S., et al. (2015). Novel HER3/MUC4 oncogenic signaling aggravates the tumorigenic phenotypes of pancreatic cancer cells. Oncotarget, 6(25), 21085–21099.CrossRefPubMedPubMedCentral
107.
Pai, P., Rachagani, S., Lakshmanan, I., Macha, M. A., Sheinin, Y., Smith, L. M., et al. (2016). The canonical Wnt pathway regulates the metastasis-promoting mucin MUC4 in pancreatic ductal adenocarcinoma. Molecular Oncology, 10(2), 224–239.CrossRefPubMed
108.
Rachagani, S., Macha, M. A., Ponnusamy, M. P., Haridas, D., Kaur, S., Jain, M., et al. (2012). MUC4 potentiates invasion and metastasis of pancreatic cancer cells through stabilization of fibroblast growth factor receptor 1. Carcinogenesis, 33(10), 1953–1964.CrossRefPubMedPubMedCentral
109.
Momi, N., Ponnusamy, M. P., Kaur, S., Rachagani, S., Kunigal, S. S., Chellappan, S., et al. (2013). Nicotine/cigarette smoke promotes metastasis of pancreatic cancer through alpha7nAChR-mediated MUC4 upregulation. Oncogene, 32(11), 1384–1395.CrossRefPubMed
110.
Moniaux, N., Chaturvedi, P., Varshney, G. C., Meza, J. L., Rodriguez-Sierra, J. F., Aubert, J. P., et al. (2007). Human MUC4 mucin induces ultra-structural changes and tumorigenicity in pancreatic cancer cells. British Journal of Cancer, 97(3), 345–357.CrossRefPubMedPubMedCentral
111.
Senapati, S., Gnanapragassam, V. S., Moniaux, N., Momi, N., & Batra, S. K. (2012). Role of MUC4-NIDO domain in the MUC4-mediated metastasis of pancreatic cancer cells. Oncogene, 31(28), 3346–3356.CrossRefPubMed
112.
Shukla, S. K., Gunda, V., Abrego, J., Haridas, D., Mishra, A., Souchek, J., et al. (2015). MUC16-mediated activation of mTOR and c-Myc reprograms pancreatic cancer metabolism. Oncotarget, 6(22), 19118–19131.CrossRefPubMedPubMedCentral
113.
Singh, A. P., Moniaux, N., Chauhan, S. C., Meza, J. L., & Batra, S. K. (2004). Inhibition of MUC4 expression suppresses pancreatic tumor cell growth and metastasis. Cancer Research, 64(2), 622–630.CrossRefPubMed
114.
Torres, M. P., Ponnusamy, M. P., Chakraborty, S., Smith, L. M., Das, S., Arafat, H. A., et al. (2010). Effects of thymoquinone in the expression of mucin 4 in pancreatic cancer cells: implications for the development of novel cancer therapies. Molecular Cancer Therapeutics, 9(5), 1419–1431.CrossRefPubMedPubMedCentral
115.
Shimizu, A., Hirono, S., Tani, M., Kawai, M., Okada, K., Miyazawa, M., et al. (2012). Coexpression of MUC16 and mesothelin is related to the invasion process in pancreatic ductal adenocarcinoma. Cancer Science, 103(4), 739–746.CrossRefPubMed
116.
Lee, J., Lee, J., Yun, J. H., Jeong, D. G., & Kim, J. H. (2016). DUSP28 links regulation of mucin 5B and mucin 16 to migration and survival of AsPC-1 human pancreatic cancer cells. Tumour Biology: the journal of the International Society for Oncodevelopmental Biology and Medicine, 37(9), 12193–12202.CrossRef
117.
Hoshi, H., Sawada, T., Uchida, M., Saito, H., Iijima, H., Toda-Agetsuma, M., et al. (2011). Tumor-associated MUC5AC stimulates in vivo tumorigenicity of human pancreatic cancer. International Journal of Oncology, 38(3), 619–627.PubMed
118.
Yamazoe, S., Tanaka, H., Sawada, T., Amano, R., Yamada, N., Ohira, M., et al. (2010). RNA interference suppression of mucin 5AC (MUC5AC) reduces the adhesive and invasive capacity of human pancreatic cancer cells. Journal of Experimental & Clinical Cancer Research: CR, 29, 53.CrossRef
119.
Chauhan, S. C., Ebeling, M. C., Maher, D. M., Koch, M. D., Watanabe, A., Aburatani, H., et al. (2012). MUC13 mucin augments pancreatic tumorigenesis. Molecular Cancer Therapeutics, 11(1), 24–33.CrossRefPubMed
120.
Wissniowski, T. T., Meister, S., Hahn, E. G., Kalden, J. R., Voll, R., & Ocker, M. (2012). Mucin production determines sensitivity to bortezomib and gemcitabine in pancreatic cancer cells. International Journal of Oncology., 40(5), 1581–1589.PubMed
121.
Nath, S., Daneshvar, K., Roy, L. D., Grover, P., Kidiyoor, A., Mosley, L., et al. (2013). MUC1 induces drug resistance in pancreatic cancer cells via upregulation of multidrug resistance genes. Oncogene, e51, 2.
122.
Roy, L. D., Sahraei, M., Subramani, D. B., Besmer, D., Nath, S., Tinder, T. L., et al. (2011). MUC1 enhances invasiveness of pancreatic cancer cells by inducing epithelial to mesenchymal transition. Oncogene, 30(12), 1449–1459.CrossRefPubMed
123.
Komatsu, M., Carraway, C. A., Fregien, N. L., & Carraway, K. L. (1997). Reversible disruption of cell-matrix and cell-cell interactions by overexpression of sialomucin complex. The Journal of Biological Chemistry, 272(52), 33245–33254.CrossRefPubMed
124.
Komatsu, M., Tatum, L., Altman, N. H., Carothers Carraway, C. A., & Carraway, K. L. (2000). Potentiation of metastasis by cell surface sialomucin complex (rat MUC4), a multifunctional anti-adhesive glycoprotein. International Journal of Cancer, 87(4), 480–486.CrossRefPubMed
125.
Price-Schiavi, S. A., Jepson, S., Li, P., Arango, M., Rudland, P. S., Yee, L., et al. (2002). Rat Muc4 (sialomucin complex) reduces binding of anti-ErbB2 antibodies to tumor cell surfaces, a potential mechanism for herceptin resistance. International Journal of Cancer, 99(6), 783–791.CrossRefPubMed
126.
Nagy, P., Friedlander, E., Tanner, M., Kapanen, A. I., Carraway, K. L., Isola, J., et al. (2005). Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. Cancer Research, 65(2), 473–482.PubMed
127.
Komatsu, M., Yee, L., & Carraway, K. L. (1999). Overexpression of sialomucin complex, a rat homologue of MUC4, inhibits tumor killing by lymphokine-activated killer cells. Cancer Research, 59(9), 2229–2236.PubMed
128.
Mukherjee, P., Pathangey, L. B., Bradley, J. B., Tinder, T. L., Basu, G. D., Akporiaye, E. T., et al. (2007). MUC1-specific immune therapy generates a strong anti-tumor response in a MUC1-tolerant colon cancer model. Vaccine, 25(9), 1607–1618.CrossRefPubMed
129.
Kimura, T., McKolanis, J. R., Dzubinski, L. A., Islam, K., Potter, D. M., Salazar, A. M., et al. (2013). MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study. Cancer Prevention Research (Philadelphia, Pa.), 6(1), 18–26.CrossRef
130.
Leng, Y., Cao, C., Ren, J., Huang, L., Chen, D., Ito, M., et al. (2007). Nuclear import of the MUC1-C oncoprotein is mediated by nucleoporin Nup62. The Journal of Biological Chemistry, 282(27), 19321–19330.CrossRefPubMed
131.
Raina, D., Ahmad, R., Joshi, M. D., Yin, L., Wu, Z., Kawano, T., et al. (2009). Direct targeting of the mucin 1 oncoprotein blocks survival and tumorigenicity of human breast carcinoma cells. Cancer Research, 69(12), 5133–5141.CrossRefPubMedPubMedCentral
132.
Ahmad, R., Alam, M., Hasegawa, M., Uchida, Y., Al-Obaid, O., Kharbanda, S., et al. (2017). Targeting MUC1-C inhibits the AKT-S6K1-elF4A pathway regulating TIGAR translation in colorectal cancer. Molecular Cancer, 16(1), 33.CrossRefPubMedPubMedCentral
133.
Choudhury, A., Singh, R. K., Moniaux, N., El-Metwally, T. H., Aubert, J. P., & Batra, S. K. (2000). Retinoic acid-dependent transforming growth factor-beta 2-mediated induction of MUC4 mucin expression in human pancreatic tumor cells follows retinoic acid receptor-alpha signaling pathway. The Journal of Biological Chemistry, 275(43), 33929–33936.CrossRefPubMed
134.
Jain, M., Venkatraman, G., Moniaux, N., Kaur, S., Kumar, S., Chakraborty, S., et al. (2011). Monoclonal antibodies recognizing the non-tandem repeat regions of the human mucin MUC4 in pancreatic cancer. PLoS One, 6(8), e23344.CrossRefPubMedPubMedCentral
135.
Gautam, S. K., Kumar, S., Cannon, A., Hall, B., Bhatia, R., Nasser, M. W., et al. (2017). MUC4 mucin—a therapeutic target for pancreatic ductal adenocarcinoma. Expert Opinion on Therapeutic Targets, 21(7), 657–669.CrossRefPubMedPubMedCentral
136.
Moniaux, N., Nollet, S., Porchet, N., Degand, P., Laine, A., & Aubert, J. P. (1999). Complete sequence of the human mucin MUC4: a putative cell membrane-associated mucin. The Biochemical Journal, 338(Pt 2), 325–333.CrossRefPubMedPubMedCentral
137.
Nollet, S., Moniaux, N., Maury, J., Petitprez, D., Degand, P., Laine, A., et al. (1998). Human mucin gene MUC4: organization of its 5′-region and polymorphism of its central tandem repeat array. The Biochemical Journal, 332(Pt 3), 739–748.CrossRefPubMedPubMedCentral
138.
Bafna, S., Singh, A. P., Moniaux, N., Eudy, J. D., Meza, J. L., & Batra, S. K. (2008). MUC4, a multifunctional transmembrane glycoprotein, induces oncogenic transformation of NIH3T3 mouse fibroblast cells. Cancer Research, 68(22), 9231–9238.CrossRefPubMedPubMedCentral
139.
Ponnusamy, M. P., Lakshmanan, I., Jain, M., Das, S., Chakraborty, S., Dey, P., et al. (2010). MUC4 mucin-induced epithelial to mesenchymal transition: a novel mechanism for metastasis of human ovarian cancer cells. Oncogene, 29(42), 5741–5754.CrossRefPubMedPubMedCentral
140.
Piessen, G., Jonckheere, N., Vincent, A., Hemon, B., Ducourouble, M. P., Copin, M. C., et al. (2007). Regulation of the human mucin MUC4 by taurodeoxycholic and taurochenodeoxycholic bile acids in oesophageal cancer cells is mediated by hepatocyte nuclear factor 1alpha. The Biochemical Journal, 402(1), 81–91.CrossRefPubMedPubMedCentral
141.
Mariette, C., Perrais, M., Leteurtre, E., Jonckheere, N., Hemon, B., Pigny, P., et al. (2004). Transcriptional regulation of human mucin MUC4 by bile acids in oesophageal cancer cells is promoter-dependent and involves activation of the phosphatidylinositol 3-kinase signalling pathway. The Biochemical Journal, 377(Pt 3), 701–708.CrossRefPubMedPubMedCentral
142.
Pai, P., Rachagani, S., Dhawan, P., Sheinin, Y. M., Macha, M. A., Qazi, A. K., et al. (2016). MUC4 is negatively regulated through the Wnt/beta-catenin pathway via the Notch effector Hath1 in colorectal cancer. Genes & Cancer, 7(5–6), 154–168.
143.
Komatsu, M., Jepson, S., Arango, M. E., Carothers Carraway, C. A., & Carraway, K. L. (2001). Muc4/sialomucin complex, an intramembrane modulator of ErbB2/HER2/Neu, potentiates primary tumor growth and suppresses apoptosis in a xenotransplanted tumor. Oncogene, 20(4), 461–470.CrossRefPubMed
144.
145.
Jonckheere, N., Perrais, M., Mariette, C., Batra, S. K., Aubert, J. P., Pigny, P., et al. (2004). A role for human MUC4 mucin gene, the ErbB2 ligand, as a target of TGF-beta in pancreatic carcinogenesis. Oncogene, 23(34), 5729–5738.CrossRefPubMed
146.
Fauquette, V., Perrais, M., Cerulis, S., Jonckheere, N., Ducourouble, M. P., Aubert, J. P., et al. (2005). The antagonistic regulation of human MUC4 and ErbB-2 genes by the Ets protein PEA3 in pancreatic cancer cells: implications for the proliferation/differentiation balance in the cells. The Biochemical Journal, 386(Pt 1), 35–45.CrossRefPubMedPubMedCentral
147.
Kaur, S., Sharma, N., Krishn, S. R., Lakshmanan, I., Rachagani, S., Baine, M. J., et al. (2014). MUC4-mediated regulation of acute phase protein lipocalin 2 through HER2/AKT/NF-kappaB signaling in pancreatic cancer. Clinical Cancer Research: an official journal of the American Association for Cancer Research, 20(3), 688–700.CrossRef
148.
Singh, A. P., Chauhan, S. C., Andrianifahanana, M., Moniaux, N., Meza, J. L., Copin, M. C., et al. (2007). MUC4 expression is regulated by cystic fibrosis transmembrane conductance regulator in pancreatic adenocarcinoma cells via transcriptional and post-translational mechanisms. Oncogene, 26(1), 30–41.CrossRefPubMed
149.
Choudhury, A., Moniaux, N., Ulrich, A. B., Schmied, B. M., Standop, J., Pour, P. M., et al. (2004). MUC4 mucin expression in human pancreatic tumours is affected by organ environment: the possible role of TGFbeta2. British Journal of Cancer, 90(3), 657–664.CrossRefPubMedPubMedCentral
150.
Joshi, S., Cruz, E., Rachagani, S., Guha, S., Brand, R. E., Ponnusamy, M. P., et al. (2016). Bile acids-mediated overexpression of MUC4 via FAK-dependent c-Jun activation in pancreatic cancer. Molecular Oncology, 10(7), 1063–1077.CrossRefPubMedPubMedCentral
151.
Andrianifahanana, M., Singh, A. P., Nemos, C., Ponnusamy, M. P., Moniaux, N., Mehta, P. P., et al. (2007). IFN-gamma-induced expression of MUC4 in pancreatic cancer cells is mediated by STAT-1 upregulation: a novel mechanism for IFN-gamma response. Oncogene, 26(51), 7251–7261.CrossRefPubMed
152.
Iacobuzio-Donahue, C. A., Ashfaq, R., Maitra, A., Adsay, N. V., Shen-Ong, G. L., Berg, K., et al. (2003). Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. Cancer Research, 63(24), 8614–8622.PubMed
153.
Swartz, M. J., Batra, S. K., Varshney, G. C., Hollingsworth, M. A., Yeo, C. J., Cameron, J. L., et al. (2002). MUC4 expression increases progressively in pancreatic intraepithelial neoplasia. American Journal of Clinical Pathology, 117(5), 791–796.CrossRefPubMed
154.
Chaturvedi, P., Singh, A. P., Chakraborty, S., Chauhan, S. C., Bafna, S., Meza, J. L., et al. (2008). MUC4 mucin interacts with and stabilizes the HER2 oncoprotein in human pancreatic cancer cells. Cancer Research, 68(7), 2065–2070.CrossRefPubMedPubMedCentral
155.
Vasseur, R., Skrypek, N., Duchene, B., Renaud, F., Martinez-Maqueda, D., Vincent, A., et al. (2015). The mucin MUC4 is a transcriptional and post-transcriptional target of K-ras oncogene in pancreatic cancer. Implication of MAPK/AP-1, NF-kappaB and RalB signaling pathways. Biochimica et Biophysica Acta, 1849(12), 1375–1384.CrossRefPubMed
156.
Rachagani, S., Torres, M. P., Kumar, S., Haridas, D., Baine, M., Macha, M. A., et al. (2012). Mucin (Muc) expression during pancreatic cancer progression in spontaneous mouse model: potential implications for diagnosis and therapy. Journal of Hematology & Oncology, 5, 68.CrossRef
157.
Singh, A. P., Chaturvedi, P., & Batra, S. K. (2007). Emerging roles of MUC4 in cancer: a novel target for diagnosis and therapy. Cancer Research, 67(2), 433–436.CrossRefPubMed
158.
Torres, M. P., Chakraborty, S., Souchek, J., & Batra, S. K. (2012). Mucin-based targeted pancreatic cancer therapy. Current Pharmaceutical Design, 18(17), 2472–2481.CrossRefPubMedPubMedCentral
159.
Carraway, K. L., Theodoropoulos, G., Kozloski, G. A., & Carothers Carraway, C. A. (2009). Muc4/MUC4 functions and regulation in cancer. Future Oncology (London, England), 5(10), 1631–1640.CrossRef
160.
Jonckheere, N., & Van Seuningen, I. (2018). Integrative analysis of the cancer genome atlas and cancer cell lines encyclopedia large-scale genomic databases: MUC4/MUC16/MUC20 signature is associated with poor survival in human carcinomas. Journal of Translational Medicine, 16(1), 259.CrossRefPubMedPubMedCentral
161.
Wei, J., Gao, W., Wu, J., Meng, K., Zhang, J., Chen, J., et al. (2008). Dendritic cells expressing a combined PADRE/MUC4-derived polyepitope DNA vaccine induce multiple cytotoxic T-cell responses. Cancer Biotherapy & Radiopharmaceuticals, 23(1), 121–128.CrossRef
162.
Wu, J., Wei, J., Meng, K., Chen, J., Gao, W., Zhang, J., et al. (2009). Identification of an HLA-A*0201-restrictive CTL epitope from MUC4 for applicable vaccine therapy. Immunopharmacology and Immunotoxicology, 31(3), 468–476.CrossRefPubMed
163.
Das, S., & Batra, S. K. (2015). Understanding the unique attributes of MUC16 (CA125): potential implications in targeted therapy. Cancer Research, 75(22), 4669–4674.CrossRefPubMedPubMedCentral
164.
O’Brien, T. J., Beard, J. B., Underwood, L. J., Dennis, R. A., Santin, A. D., & York, L. (2001). The CA 125 gene: an extracellular superstructure dominated by repeat sequences. Tumour Biology: the journal of the International Society for Oncodevelopmental Biology and Medicine, 22(6), 348–366.CrossRef
165.
O’Brien, T. J., Beard, J. B., Underwood, L. J., & Shigemasa, K. (2002). The CA 125 gene: a newly discovered extension of the glycosylated N-terminal domain doubles the size of this extracellular superstructure. Tumour Biology: the journal of the International Society for Oncodevelopmental Biology and Medicine, 23(3), 154–169.CrossRef
166.
Yin, B. W., Dnistrian, A., & Lloyd, K. O. (2002). Ovarian cancer antigen CA125 is encoded by the MUC16 mucin gene. International Journal of Cancer, 98(5), 737–740.CrossRefPubMed
167.
Haridas, D., Ponnusamy, M. P., Chugh, S., Lakshmanan, I., Seshacharyulu, P., & Batra, S. K. (2014). MUC16: molecular analysis and its functional implications in benign and malignant conditions. FASEB Journal: official publication of the Federation of American Societies for Experimental Biology, 28(10), 4183–4199.CrossRef
168.
Streppel, M. M., Vincent, A., Mukherjee, R., Campbell, N. R., Chen, S. H., Konstantopoulos, K., et al. (2012). Mucin 16 (cancer antigen 125) expression in human tissues and cell lines and correlation with clinical outcome in adenocarcinomas of the pancreas, esophagus, stomach, and colon. Human Pathology, 43(10), 1755–1763.CrossRefPubMedPubMedCentral
169.
Aithal, A., Rauth, S., Kshirsagar, P., Shah, A., Lakshmanan, I., Junker, W. M., et al. (2018). MUC16 as a novel target for cancer therapy. Expert Opinion on Therapeutic Targets, 22(8), 675–686.CrossRefPubMedPubMedCentral
170.
Haridas, D., Chakraborty, S., Ponnusamy, M. P., Lakshmanan, I., Rachagani, S., Cruz, E., et al. (2011). Pathobiological implications of MUC16 expression in pancreatic cancer. PLoS One, 6(10), e26839.CrossRefPubMedPubMedCentral
171.
Bafna, S., Kaur, S., & Batra, S. K. (2010). Membrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cells. Oncogene, 29(20), 2893–2904.CrossRefPubMedPubMedCentral
172.
Matte, I., Lane, D., Boivin, M., Rancourt, C., & Piche, A. (2014). MUC16 mucin (CA125) attenuates TRAIL-induced apoptosis by decreasing TRAIL receptor R2 expression and increasing c-FLIP expression. BMC Cancer, 14, 234.CrossRefPubMedPubMedCentral
173.
Boivin, M., Lane, D., Piche, A., & Rancourt, C. (2009). CA125 (MUC16) tumor antigen selectively modulates the sensitivity of ovarian cancer cells to genotoxic drug-induced apoptosis. Gynecologic Oncology, 115(3), 407–413.CrossRefPubMed
174.
Berek, J. S., Taylor, P. T., Gordon, A., Cunningham, M. J., Finkler, N., Orr, J., Jr., et al. (2004). Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. Journal of Clinical Oncology: official journal of the American Society of Clinical Oncology, 22(17), 3507–3516.CrossRef
175.
Sabbatini, P., Harter, P., Scambia, G., Sehouli, J., Meier, W., Wimberger, P., et al. (2013). Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO—the MIMOSA study. Journal of Clinical Oncology : official journal of the American Society of Clinical Oncology, 31(12), 1554–1561.CrossRef
176.
Das, S., Majhi, P. D., Al-Mugotir, M. H., Rachagani, S., Sorgen, P., & Batra, S. K. (2015). Membrane proximal ectodomain cleavage of MUC16 occurs in the acidifying Golgi/post-Golgi compartments. Scientific Reports, 5, 9759.CrossRefPubMedPubMedCentral
177.
Garg, G., Gibbs, J., Belt, B., Powell, M. A., Mutch, D. G., Goedegebuure, P., et al. (2014). Novel treatment option for MUC16-positive malignancies with the targeted TRAIL-based fusion protein Meso-TR3. BMC Cancer, 14, 35.CrossRefPubMedPubMedCentral
178.
Thiery, J. P., & Sleeman, J. P. (2006). Complex networks orchestrate epithelial-mesenchymal transitions. Nature Reviews. Molecular Cell Biology, 7(2), 131–142.CrossRefPubMed
179.
Thiery, J. P., Acloque, H., Huang, R. Y., & Nieto, M. A. (2009). Epithelial-mesenchymal transitions in development and disease. Cell, 139(5), 871–890.CrossRefPubMed
180.
Ahmed, N., Abubaker, K., Findlay, J., & Quinn, M. (2010). Epithelial mesenchymal transition and cancer stem cell-like phenotypes facilitate chemoresistance in recurrent ovarian cancer. Current Cancer Drug Targets, 10(3), 268–278.CrossRefPubMed
181.
Lim, S., Becker, A., Zimmer, A., Lu, J., Buettner, R., & Kirfel, J. (2013). SNAI1-mediated epithelial-mesenchymal transition confers chemoresistance and cellular plasticity by regulating genes involved in cell death and stem cell maintenance. PLoS One, 8(6), e66558.CrossRefPubMedPubMedCentral
182.
Voulgari, A., & Pintzas, A. (2009). Epithelial-mesenchymal transition in cancer metastasis: mechanisms, markers and strategies to overcome drug resistance in the clinic. Biochimica et Biophysica Acta, 1796(2), 75–90.PubMed
183.
Yamada, S., Fuchs, B. C., Fujii, T., Shimoyama, Y., Sugimoto, H., Nomoto, S., et al. (2013). Epithelial-to-mesenchymal transition predicts prognosis of pancreatic cancer. Surgery, 154(5), 946–954.CrossRefPubMed
184.
Ponnusamy, M. P., Seshacharyulu, P., Lakshmanan, I., Vaz, A. P., Chugh, S., & Batra, S. K. (2013). Emerging role of mucins in epithelial to mesenchymal transition. Current Cancer Drug Targets, 13(9), 945–956.CrossRefPubMedPubMedCentral
185.
Rajabi, H., Alam, M., Takahashi, H., Kharbanda, A., Guha, M., Ahmad, R., et al. (2014). MUC1-C oncoprotein activates the ZEB1/miR-200c regulatory loop and epithelial-mesenchymal transition. Oncogene, 33(13), 1680–1689.CrossRefPubMed
186.
Gnemmi, V., Bouillez, A., Gaudelot, K., Hemon, B., Ringot, B., Pottier, N., et al. (2014). MUC1 drives epithelial-mesenchymal transition in renal carcinoma through Wnt/beta-catenin pathway and interaction with SNAIL promoter. Cancer Letters, 346(2), 225–236.CrossRefPubMed
187.
Gao, L., Liu, J., Zhang, B., Zhang, H., Wang, D., Zhang, T., et al. (2014). Functional MUC4 suppress epithelial-mesenchymal transition in lung adenocarcinoma metastasis. Tumour Biology: the journal of the International Society for Oncodevelopmental Biology and Medicine, 35(2), 1335–1341.CrossRef
188.
Jonckheere, N., & Van Seuningen, I. (2014). Comment on: Functional MUC4 suppress epithelial-mesenchymal transition in lung adenocarcinoma metastasis. Gao L, Liu J, Zhang B, Zhang H, Wang D, Zhang T, Liu Y, Wang C. Tumour Biol. 2013, in press. Tumour Biology: the journal of the International Society for Oncodevelopmental Biology and Medicine, 35(4), 3941–3942.CrossRef
189.
Comamala, M., Pinard, M., Theriault, C., Matte, I., Albert, A., Boivin, M., et al. (2011). Downregulation of cell surface CA125/MUC16 induces epithelial-to-mesenchymal transition and restores EGFR signalling in NIH:OVCAR3 ovarian carcinoma cells. British Journal of Cancer, 104(6), 989–999.CrossRefPubMedPubMedCentral
190.
Theriault, C., Pinard, M., Comamala, M., Migneault, M., Beaudin, J., Matte, I., et al. (2011). MUC16 (CA125) regulates epithelial ovarian cancer cell growth, tumorigenesis and metastasis. Gynecologic Oncology, 121(3), 434–443.CrossRefPubMed
Metadata
Title
Mucin glycoproteins block apoptosis; promote invasion, proliferation, and migration; and cause chemoresistance through diverse pathways in epithelial cancers
Authors
Ian S. Reynolds
Michael Fichtner
Deborah A. McNamara
Elaine W. Kay
Jochen H.M. Prehn
John P. Burke
Publication date
01-06-2019
Publisher
Springer US
Published in
Cancer and Metastasis Reviews / Issue 1-2/2019
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-019-09781-w

Other articles of this Issue 1-2/2019

Cancer and Metastasis Reviews 1-2/2019 Go to the issue

ReviewPaper

Causes, consequences, and therapy of tumors acidosis

NON-THEMATIC REVIEW

Cancer-associated mucins: role in immune modulation and metastasis

ReviewPaper

Pro- and antitumor effects of mitochondrial reactive oxygen species

OriginalPaper

Tumor pH and metastasis: a malignant process beyond hypoxia

ReviewPaper

Intracellular pH dynamics and charge-changing somatic mutations in cancer

Correction

Correction to: mTOR co-targeting strategies for head and neck cancer therapy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits